Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
J. Iribarren, P. Labarga, R. Rubio, J. Berenguer, J.M. Miró, A. Antela, et al.
Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en pacientes adultos infectados por el virus de la inmunodeficiencia humana (Octubre 2004.
Enferm Infecc Microbiol Clin, 22 (2004), pp. 564-642
[2.]
http://hivinsite.ucsf.edu/global, accessed October 11, 2004
[3.]
http://www.paho.org/Spanish/AD/FCH/AI/acceso-arv-05.pdf, accessed October 11, 2004
[4.]
C. Zala, C. Alexander, C. Ochoa, S. Gullemi, L. Ting, J. Asselin, et al.
11th Conference on Retrovirus and Opportunistic Infections, (2004),
[5.]
M. Rubio, J. Berenguer, J.M. Miró.
Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en pacientes adultos infectados por el virus de la inmunodeficiencia humana en el año 2002.
Enferm Infecc Microbiol Clin, 20 (2002), pp. 244-303
[6.]
R.M. Gulick, H.J. Ribaudo, C.M. Shikuma, S. Lustgarten, K.E. Squires, III W.A. Meyer, et al.
Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection.
N Engl J Med, 350 (2004), pp. 1850-1861
[7.]
J.E. Gallant, A.E. Rodríguez, W. Weinberg, B. Young, D. Berger, M.L. Lim, et al.
43th ICAAC, (2003),
[8.]
Gilead.
High rate of virologic failure in patients with HIV infection treated with a once-daily triple NRTI regimen containing didanosine, lamivudine, and tenofovir.
Gilead Sciences, October 14, (2003),
[9.]
F. Van Leth, P. Phanuphak, K. Ruxrungtham, E. Baraldi, S. Miller, B. Gazzard, et al.
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
Lancet, 363 (2004), pp. 1253-1263
[10.]
Leth Van, S. Andrews, B. Grinsztejn, E. Wilkins, M. Lazanas, J. Lange, et al.
Program and Abstracts 11th Conference on Retrovirus and Opportunistic Infections, (2004),
[11.]
C. Hicks, M.S. King, R.M. Gulick, A.C. White Jr, J.J. Eron Jr, H.A. Kessler, et al.
Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study.
AIDS, 18 (2004), pp. 775-779
[12.]
S. Walmsley, B. Bernstein, M. King, J. Arribas, G. Beall, P. Ruane, et al.
Lopinavir-ritonavir versus nelfinavir for the initial treatment HIV infection.
N Engl J Med, 346 (2002), pp. 2039-2046
[13.]
J.C. Gathe Jr, P. Ive, R. Wood, D. Schurmann, N.C. Bellos, E. De Jesús, et al.
SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.
AIDS, 18 (2004), pp. 1529-1537
[14.]
R. Wood, P. Phanuphak, P. Cahn, V. Pokrovskiy, W. Rozenbaum, G. Pantaleo, et al.
long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir.
J Acquir Immune Defic Syndr, 36 (2004), pp. 684-692
[15.]
J.M. Molina, F. Ferchal, C. Rancinan, P. Yeni, W. Rozenbaum, V. Journot, et al.
10th Conference on Retrovirus and Opportunistic Infections, (2003),
[16.]
M. Ceriotto, M. Rolón, E. Warley, R. Corazza, M. Natiello, C. Mayoral, et al.
Abstract book; XV Int Conference on AIDS, (2004),
Copyright © 2004. Elsevier España, S.L.. Todos los derechos reservados
